US20090234005A1 - Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient - Google Patents
Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient Download PDFInfo
- Publication number
- US20090234005A1 US20090234005A1 US11/887,037 US88703706A US2009234005A1 US 20090234005 A1 US20090234005 A1 US 20090234005A1 US 88703706 A US88703706 A US 88703706A US 2009234005 A1 US2009234005 A1 US 2009234005A1
- Authority
- US
- United States
- Prior art keywords
- derivative
- group
- prostaglandin
- cell
- retinal neuronal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound *CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 0.000 description 4
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a protective agent for a retinal neuronal cell containing a prostaglandin F2 ⁇ derivative as an active ingredient.
- the retina is a tissue with a thickness of from 0.1 to 0.5 mm consisting of ten layers of inner limiting membrane, nerve fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, outer limiting membrane, photoreceptor cell layer and retinal pigment epithelium layer, and retinal neuronal cell groups including photoreceptor cells, bipolar cells, ganglion cells, horizontal cells, amacrine cells and Muller cells are present therein.
- the retinal neuronal cells play an important role in the reception and transmission of visual information such as converting light stimulation into an electrical signal and transmitting the signal to the brain.
- the visual information from the eyes is converted into an electrical signal through photoreceptor cells and transmitted to ganglion cells by way of horizontal cells, bipolar cells and/or amacrine cells. Then, the electrical signal is transmitted to the brain by way of the optic nerve which is a bundle of optic nerve fibers including axons of ganglion cells.
- retinal neuronal cells when these retinal neuronal cells are damaged due to various causes, the homeostasis (a function to supply oxygen or nutrition to retinal neuronal cells through retinal blood circulation, and the like) of retinal neuronal cells cannot be maintained, and the transmission of visual information to the brain is inhibited.
- dysfunction of retinal neuronal cells is caused in various retinal diseases such as retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, glaucoma, macular degeneration, retinitis pigmentosa and Leber's disease (Brain Res. Bull., 62(6), 447-453 (2004)).
- retinal neuronal cell death due to retinal ischemia is one of the causes of retinal neuronal cell damage, and the following events have been reported regarding the retinal neuronal cell death due to retinal ischemia (JP-A-2003-146904 and Nature Rev., 2, 448-459 (2003)).
- retinal neuronal cell death due to retinal ischemia is similar to that of cerebral neuronal cell death due to cerebral ischemia.
- retinal inner layer In short term retinal ischemia, the retinal inner layer (inner plexiform layer) is selectively damaged.
- NMDA retinal N-methyl-D-aspartate
- a drug such as a glutamate neurotoxicity inhibitor, an NMDA receptor antagonist or an NO synthesis inhibitor is useful for treating an eye disease caused by retinal neuronal cell damage, and various studies have been carried out.
- JP-A-2001-072591 discloses a protective agent for a retinal neuronal cell containing nipradilol which is one of the ⁇ -blockers as an active ingredient.
- WO 01/056606 discloses a protective agent for an optic ganglion cell containing an interleukin-1 receptor antagonist protein as an active ingredient.
- WO 03/004058 discloses a protective agent for an optic ganglion cell containing an ⁇ 1 receptor antagonist such as brimonidine hydrochloride as an active ingredient.
- Experimental Eye Res., 72, 479-486 discloses a nerve-protecting effect of latanoprost which is one of the prostaglandin derivatives, etc.
- prostaglandin F2 ⁇ derivatives are disclosed as a therapeutic agent for glaucoma having an intraocular pressure lowering action in JP-A-59-1418, JP-T-3-501025, JP-T-8-501310, JP-A-10-182465, WO 98/12175, European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771 and JP-A-2003-321442.
- JP-A-59-1418 discloses a natural prostaglandin F2 ⁇ derivative.
- JP-T-3-501025 discloses a latanoprost-related compound.
- JP-T-8-501310 discloses a bimatoprost-related compound.
- JP-A-10-182465 discloses a travoprost-related compound.
- WO 98/12175 discloses a monofluoroprostaglandin F2 ⁇ derivative.
- European Patent Application Publication No. 850926 and JP-A-2004-002462 disclose a difluoroprostaglandin F2 ⁇ derivative.
- JP-A-10-259179 discloses a fluorine-containing prostaglandin F2 ⁇ derivative having a multisubstituted aryloxy group.
- JP-A-2002-293771 discloses an ether type difluoroprostaglandin F2 ⁇ derivative.
- JP-A-2003-321442 discloses a difluoroprostaglandin F2 ⁇ amide derivative.
- any of these documents does not describe an effect of a fluorine-containing prostaglandin F2 ⁇ derivative on protecting a retinal neuronal cell at all.
- the present inventors made intensive studies in order to find a new pharmaceutical application of a prostaglandin F2 ⁇ derivative. As a result, they found that the prostaglandin F2 ⁇ derivative inhibits glutamate-induced retinal neuronal cell death in a concentration-dependent manner in rat fetal retinal neuronal cells, in other words, the prostaglandin F2 ⁇ derivative acts directly on the retinal neuronal cells and exhibits a protective effect, thus accomplished the present invention.
- the present invention relates to a protective agent for a retinal neuronal cell containing a prostaglandin F2 ⁇ derivative as an active ingredient.
- the present invention relates to a method of protecting a retinal neuronal cell and a method of preventing or treating an eye disease associated with retinal neuronal cell damage.
- the “prostaglandin F2 ⁇ derivative” means a prostaglandin F2 ⁇ -related compound derived from the skeleton of prostanoic acid.
- a protective agent for a retinal neuronal cell is, for example, one which contains a prostaglandin F2 ⁇ derivative or a salt thereof such as a natural prostaglandin F2 ⁇ derivative disclosed in JP-A-59-1418, a latanoprost-related compound (with the proviso that a latanoprost-related compound or a salt thereof excluding latanoprost) disclosed in JP-T-3-501025, a bimatoprost-related compound (preferably bimatoprost or a salt thereof) disclosed in JP-T-8-501310, a travoprost-related compound (preferably travoprost or a salt thereof) disclosed in JP-A-10-182465, or a fluorine-containing prostaglandin F2 ⁇ derivative disclosed in WO 98/12175, European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002
- a protective agent for a retinal neuronal cell is, for example, one which contains a “fluorine-containing prostaglandin F2 ⁇ derivative” as an active ingredient.
- the “fluorine-containing prostaglandin F2 ⁇ derivative” means a prostaglandin F2 ⁇ derivative having one or more fluorine atoms.
- a protective agent for a retinal neuronal cell is, for example, one which contains a fluorine-containing prostaglandin F2 ⁇ derivative disclosed in WO 98/12175, European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771 or JP-A-2003-321442 as an active ingredient.
- a protective agent for a retinal neuronal cell is, for example, one which contains a 15,15-difluoroprostaglandin F2 ⁇ derivative disclosed in European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771 or JP-A-2003-321442 as an active ingredient.
- a further more preferred protective agent for a retinal neuronal cell is, for example, one which contains a 15,15-difluoroprostaglandin F2 ⁇ derivative represented by the following general formula (I), which is a further more preferred fluorine-containing prostaglandin F2 ⁇ derivative or a salt thereof, as an active ingredient.
- a 15,15-difluoroprostaglandin F2 ⁇ derivative represented by the following general formula (I) which is a further more preferred fluorine-containing prostaglandin F2 ⁇ derivative or a salt thereof, as an active ingredient.
- R represents a hydroxyalkyl group, a formyl group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group, and when R is an aryloxycarbonyl group or an arylaminocarbonyl group, the aryl moiety thereof may have a substituent.
- R represents a hydroxyalkyl group, a formyl group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group, and when R is an aryloxycarbonyl group or an arylaminocarbonyl group, the aryl moiety thereof may have a substituent.
- R represents a hydroxyalkyl group, a formyl group, a carboxy group, an alkoxy
- halogen refers to fluorine, chlorine, bromine or iodine.
- alkyl refers to straight-chain or branched alkyl having 1 to 6 carbon atoms. Specific examples thereof include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl and the like.
- alkoxy refers to straight-chain or branched alkoxy having 1 to 6 carbon atoms. Specific examples thereof include methoxy, ethoxy, n-propoxy, n-butoxy, n-pentyloxy, n-hexyloxy, isopropoxy, isobutoxy, sec-butoxy, tert-butoxy, isopentyloxy and the like.
- aryl refers to monocyclic aromatic hydrocarbon, or bicyclic or tricyclic condensed polycyclic aromatic hydrocarbon having 6 to 14 carbon atoms. Specific examples thereof include phenyl, naphthyl, anthryl, phenanthryl and the like.
- aryloxy refers to monocyclic aromatic hydrocarbonoxy, or bicyclic or tricyclic condensed polycyclic aromatic hydrocarbonoxy having 6 to 14 carbon atoms. Specific examples thereof include phenoxy, naphthyloxy, anthryloxy, phenanthryloxy and the like.
- alkylamino refers to monoalkylamino or dialkylamino having 1 to 12 carbon atoms. Specific examples thereof include methylamino, ethylamino, dimethylamino, dihexylamino and the like.
- arylamino refers to monoarylamino or diarylamino having 6 to 28 carbon atoms. Specific examples thereof include phenylamino, naphthylamino, methylphenylamino, ethylphenylamino, diphenylamino, dianthrylamino and the like.
- R is an “aryloxycarbonyl group” or an “arylaminocarbonyl group”
- the aryl moiety thereof may have a substituent.
- the substituent an atom or a group selected from a halogen atom, an alkyl group, a halogenated alkyl group and an alkoxy group is preferred, and the number of the substituents is preferably 1 to 3.
- a further more preferred fluorine-containing prostaglandin F2 ⁇ derivative is, for example, a 15,15-difluoroprostaglandin F2 ⁇ derivative of the above-mentioned general formula (I) in which R represents a carboxy group or a salt group thereof or an alkoxycarbonyl group.
- a particularly preferred fluorine-containing prostaglandin F2 ⁇ derivative is, for example, a 15,15-difluoroprostaglandin F2 ⁇ derivative of the above-mentioned general formula (I) in which R represents a carboxy group or a salt group thereof or an isopropoxycarbonyl group.
- another preferred compound is, for example, a 15-monofluoroprostaglandin F2 ⁇ derivative described in the above-mentioned WO 98/12175.
- prostaglandin F2 ⁇ derivatives can be in the form of a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid or phosphoric acid, an organic acid such as acetic acid, fumalic acid, maleic acid, succinic acid or citric acid, an alkali metal such as lithium, sodium or potassium, an alkaline earth metal such as calcium or magnesium, ammonia or the like.
- an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid or phosphoric acid
- an organic acid such as acetic acid, fumalic acid, maleic acid, succinic acid or citric acid
- an alkali metal such as lithium, sodium or potassium
- an alkaline earth metal such as calcium or magnesium, ammonia or the like.
- the “retinal neuronal cell” means a neuronal cell involved in the transmission of visual signal to the brain. Specifically, it means a photoreceptor cell, a horizontal cell, a bipolar cell, an optic ganglion cell, an amacrine cell or the like.
- the “eye disease” means an eye disease associated with retinal neuronal cell damage.
- abnormal visual field retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, glaucoma, macular degeneration, retinitis pigmentosa, Leber's disease or the like
- abnormal visual field retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa or Leber's disease.
- the protective agent for a retinal neuronal cell of the present invention can be administered orally or parenterally.
- the dosage form for administration include an eye drop, an ophthalmic ointment, an injection, a tablet, a capsule, a granule, a powder, and the like, and particularly preferred is an eye drop.
- Such a preparation can be prepared by any of widely used techniques, for example, a technique disclosed in JP-A-59-1418, JP-T-3-501025, JP-T-8-501310, JP-A-10-182465, WO 98/12175, European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771, JP-A-2003-321442, WO 2/22131 or the like.
- an eye drop can be prepared using a tonisity agent such as sodium chloride or concentrated glycerin, a buffer such as sodium phosphate or sodium acetate, a surfactant such as polyoxyethylene sorbitan monooleate, polyoxyl 40 stearate or polyoxyethylene hydrogenated castor oil, a stabilizer such as sodium citrate or sodium edetate, a preservative such as benzalkonium chloride or paraben according to need.
- a tonisity agent such as sodium chloride or concentrated glycerin
- a buffer such as sodium phosphate or sodium acetate
- a surfactant such as polyoxyethylene sorbitan monooleate, polyoxyl 40 stearate or polyoxyethylene hydrogenated castor oil
- a stabilizer such as sodium citrate or sodium edetate
- a preservative such as benzalkonium chloride or paraben according to need.
- the pH of the eye drop is permitted as long as it falls within the range that is acceptable
- An ophthalmic ointment can be prepared using a widely used base such as white soft paraffin or liquid paraffin according to need.
- an oral preparation such as a tablet, a capsule, a granule or a powder
- an extender such as lactose, crystalline cellulose, starch or a vegetable oil, a lubricant such as magnesium stearate or talc, a binder such as hydroxypropyl cellulose, or polyvinylpyrrolidone, a disintegrant such as carboxymethyl cellulose calcium or low-substituted hydroxypropylmethyl cellulose, a coating agent such as hydroxypropylmethyl cellulose, macrogol or a silicone resin, a film forming agent such as gelatin film, or the like according to need.
- an extender such as lactose, crystalline cellulose, starch or a vegetable oil
- a lubricant such as magnesium stearate or talc
- a binder such as hydroxypropyl cellulose, or polyvinylpyrrolidone
- a disintegrant such as carboxymethyl cellulose calcium or low-substitute
- the dose can be appropriately selected depending on the symptoms, age, dosage form and the like.
- An eye drop may be instilled once to several times a day at a concentration of from 0.00001 to 1% (w/v), preferably from 0.0001 to 1% (w/v).
- An oral preparation may be administered once or divided into several times at a dose of generally from 0.01 to 5000 mg per day, preferably from 0.1 to 1000 mg per day.
- the prostaglandin F2 ⁇ derivative inhibited the glutamate-induced retinal neuronal cell death in a concentration-dependent manner. That is, the prostaglandin F2 ⁇ derivative has an action of protecting a retinal neuronal cell, and is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage.
- a desired eye drop can be obtained by appropriately changing the kinds and the amounts of the prostaglandin F2 ⁇ derivative and additives.
- a desired ophthalmic ointment can be obtained by appropriately changing the kinds and the amounts of the prostaglandin F2 ⁇ derivative and additives.
- prostaglandin F2 ⁇ derivative which is a test compound
- 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranor-prostaglandin F2 ⁇ was used.
- a pregnant SD rat was subjected to laparotomy under systemic anesthesia, and the uterus was transferred to a dish containing Hanks's balanced salt solution (HBSS).
- HBSS Hanks's balanced salt solution
- a rat fetus was isolated from the uterus, and the eyeballs of the rat fetus were taken out.
- the retina was isolated from the eyeballs under a stereoscopic microscope and cut into pieces with a surgical knife. Then, the retina was further broken down to the cellular level and passed through a nylon mesh (No. 305, manufactured by NBC Industries Co., Ltd.) to remove cell aggregates, and then, the resulting filtrate was centrifuged at 1000 rpm for 4 minutes.
- a nylon mesh No. 305, manufactured by NBC Industries Co., Ltd.
- the supernatant was removed, and an appropriate amount of a modified Eagle's medium (MEM) containing 10% fetal bovine serum (FBS) was added to the remaining cells to suspend them. After the cell number was counted with a hemocytometer, an MEM medium containing 10% FBS was added thereto, whereby a cell suspension with a cell density of 0.8 ⁇ 10 6 cells/mL was obtained.
- the cell suspension was inoculated in an amount of 80 ⁇ L each into polyethylenimine-coated plastic discs, and the discs were allowed to stand in an incubator (37° C., 5% CO 2 ). The day of cell inoculation was designated as day 1 of culture, and medium replacement was carried out on even number days.
- MEM modified Eagle's medium
- FBS fetal bovine serum
- an MEM medium containing 10% FBS was used, and after day 8, an MEM medium containing 10% horse serum (HS) was used.
- an MEM medium containing 10% horse serum (HS) was used on day 6, 6 mL of a medium containing cytarabine (Ara-C) (1.5 ⁇ 10 ⁇ 5 M in an MEM medium containing 10% FBS) was used for removing proliferative cells.
- test compound 2 mg was dissolved in 100% ethanol, and the resulting solution was sequentially diluted with an HS-containing MEM medium, whereby an HS-containing MEM medium containing the test compound at 0.1 nM, 1 nM, 10 nM or 100 nM was prepared.
- test compound 2 mg was dissolved in 100% ethanol, and the resulting solution was sequentially diluted with a serum-free MEM medium, whereby a serum-free MEM medium containing the test compound at 0.1 nM, 1 nM, 10 nM or 100 nM was prepared.
- the plastic discs in which cells were inoculated and cultured were transferred to the HS-containing MEM medium containing the test compound and incubated for 24 hours (37° C., 5% CO 2 ).
- the plastic discs were transferred to a serum-free MEM medium containing 1 mM glutamate and incubated for 10 minutes, and then transferred to the serum-free MEM medium containing the test compound and incubated for 1 hour (37° C., 5% CO 2 ).
- the cells were stained with a 1.5% trypan blue solution for 10 minutes and fixed by adding a 10% formalin fixative solution thereto. After the cells were washed with a physiological saline solution, stained cells and unstained cells were counted under an inverted microscope.
- a vehicle administration group was prepared by carrying out the same test as described above except that an HS-containing MEM medium was used instead of the above-mentioned HS-containing MEM medium containing the test compound and a serum-free MEM medium was used instead of the above-mentioned serum-free MEM medium containing the test compound.
- an untreated group was prepared by carrying out the same test as described above except that an HS-containing MEM medium was used instead of the above-mentioned HS-containing MEM medium containing the test compound and a serum-free MEM medium was used instead of the above-mentioned serum-free MEM medium containing the test compound, and further a treatment with a serum-free MEM medium containing glutamate was not carried out.
- the survival rate was calculated based on the following calculation equation.
- FIG. 1 is a graph showing the survival rate for each concentration in the case of using the test compound by the addition of glutamate.
Abstract
Description
- The present invention relates to a protective agent for a retinal neuronal cell containing a prostaglandin F2α derivative as an active ingredient.
- The retina is a tissue with a thickness of from 0.1 to 0.5 mm consisting of ten layers of inner limiting membrane, nerve fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, outer limiting membrane, photoreceptor cell layer and retinal pigment epithelium layer, and retinal neuronal cell groups including photoreceptor cells, bipolar cells, ganglion cells, horizontal cells, amacrine cells and Muller cells are present therein.
- The retinal neuronal cells play an important role in the reception and transmission of visual information such as converting light stimulation into an electrical signal and transmitting the signal to the brain.
- To specifically describe the mechanism of such transmission, the visual information from the eyes is converted into an electrical signal through photoreceptor cells and transmitted to ganglion cells by way of horizontal cells, bipolar cells and/or amacrine cells. Then, the electrical signal is transmitted to the brain by way of the optic nerve which is a bundle of optic nerve fibers including axons of ganglion cells.
- On the other hand, when these retinal neuronal cells are damaged due to various causes, the homeostasis (a function to supply oxygen or nutrition to retinal neuronal cells through retinal blood circulation, and the like) of retinal neuronal cells cannot be maintained, and the transmission of visual information to the brain is inhibited. For example, it is widely known that dysfunction of retinal neuronal cells is caused in various retinal diseases such as retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, glaucoma, macular degeneration, retinitis pigmentosa and Leber's disease (Brain Res. Bull., 62(6), 447-453 (2004)).
- It has recently been considered that retinal neuronal cell death due to retinal ischemia is one of the causes of retinal neuronal cell damage, and the following events have been reported regarding the retinal neuronal cell death due to retinal ischemia (JP-A-2003-146904 and Nature Rev., 2, 448-459 (2003)).
- 1) The mechanism of retinal neuronal cell death due to retinal ischemia is similar to that of cerebral neuronal cell death due to cerebral ischemia.
- 2) In short term retinal ischemia, the retinal inner layer (inner plexiform layer) is selectively damaged.
- 3) The excess release of glutamate during retinal ischemia can be observed.
- 4) By injecting an excitatory amino acid such as glutamate into the vitreous body, retinal neuronal cell death is induced.
- 5) The overstimulation mediated by retinal N-methyl-D-aspartate (NMDA) receptors promotes calcium (Ca) influx into cells, which results in inducing cell damage by way of induction of nitrogen monoxide (NO).
- From these events, it is considered that a drug such as a glutamate neurotoxicity inhibitor, an NMDA receptor antagonist or an NO synthesis inhibitor is useful for treating an eye disease caused by retinal neuronal cell damage, and various studies have been carried out.
- For example, JP-A-2001-072591 discloses a protective agent for a retinal neuronal cell containing nipradilol which is one of the β-blockers as an active ingredient. WO 01/056606 discloses a protective agent for an optic ganglion cell containing an interleukin-1 receptor antagonist protein as an active ingredient. WO 03/004058 discloses a protective agent for an optic ganglion cell containing an α1 receptor antagonist such as brimonidine hydrochloride as an active ingredient. Experimental Eye Res., 72, 479-486 (2001) discloses a nerve-protecting effect of latanoprost which is one of the prostaglandin derivatives, etc.
- On the other hand, prostaglandin F2α derivatives are disclosed as a therapeutic agent for glaucoma having an intraocular pressure lowering action in JP-A-59-1418, JP-T-3-501025, JP-T-8-501310, JP-A-10-182465, WO 98/12175, European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771 and JP-A-2003-321442. JP-A-59-1418 discloses a natural prostaglandin F2α derivative. JP-T-3-501025 discloses a latanoprost-related compound. JP-T-8-501310 discloses a bimatoprost-related compound. JP-A-10-182465 discloses a travoprost-related compound. WO 98/12175 discloses a monofluoroprostaglandin F2α derivative. European Patent Application Publication No. 850926 and JP-A-2004-002462 disclose a difluoroprostaglandin F2α derivative. JP-A-10-259179 discloses a fluorine-containing prostaglandin F2α derivative having a multisubstituted aryloxy group. JP-A-2002-293771 discloses an ether type difluoroprostaglandin F2α derivative. JP-A-2003-321442 discloses a difluoroprostaglandin F2α amide derivative.
- However, any of these documents does not describe an effect of a fluorine-containing prostaglandin F2α derivative on protecting a retinal neuronal cell at all.
- It is a very interesting subject to find a new pharmaceutical application of a prostaglandin F2α derivative (particularly a fluorine-containing prostaglandin F2α).
- Accordingly, the present inventors made intensive studies in order to find a new pharmaceutical application of a prostaglandin F2α derivative. As a result, they found that the prostaglandin F2α derivative inhibits glutamate-induced retinal neuronal cell death in a concentration-dependent manner in rat fetal retinal neuronal cells, in other words, the prostaglandin F2α derivative acts directly on the retinal neuronal cells and exhibits a protective effect, thus accomplished the present invention.
- The present invention relates to a protective agent for a retinal neuronal cell containing a prostaglandin F2α derivative as an active ingredient.
- Further, the present invention relates to a method of protecting a retinal neuronal cell and a method of preventing or treating an eye disease associated with retinal neuronal cell damage.
- In the present invention, the “prostaglandin F2α derivative” means a prostaglandin F2α-related compound derived from the skeleton of prostanoic acid.
- Specifically, a protective agent for a retinal neuronal cell is, for example, one which contains a prostaglandin F2α derivative or a salt thereof such as a natural prostaglandin F2α derivative disclosed in JP-A-59-1418, a latanoprost-related compound (with the proviso that a latanoprost-related compound or a salt thereof excluding latanoprost) disclosed in JP-T-3-501025, a bimatoprost-related compound (preferably bimatoprost or a salt thereof) disclosed in JP-T-8-501310, a travoprost-related compound (preferably travoprost or a salt thereof) disclosed in JP-A-10-182465, or a fluorine-containing prostaglandin F2α derivative disclosed in WO 98/12175, European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771 or JP-A-2003-321442 as an active ingredient.
- Preferably, a protective agent for a retinal neuronal cell is, for example, one which contains a “fluorine-containing prostaglandin F2α derivative” as an active ingredient. The “fluorine-containing prostaglandin F2α derivative” means a prostaglandin F2α derivative having one or more fluorine atoms.
- Specifically, a protective agent for a retinal neuronal cell is, for example, one which contains a fluorine-containing prostaglandin F2α derivative disclosed in WO 98/12175, European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771 or JP-A-2003-321442 as an active ingredient.
- More preferably, a protective agent for a retinal neuronal cell is, for example, one which contains a 15,15-difluoroprostaglandin F2α derivative disclosed in European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771 or JP-A-2003-321442 as an active ingredient.
- A further more preferred protective agent for a retinal neuronal cell is, for example, one which contains a 15,15-difluoroprostaglandin F2α derivative represented by the following general formula (I), which is a further more preferred fluorine-containing prostaglandin F2α derivative or a salt thereof, as an active ingredient.
- [R represents a hydroxyalkyl group, a formyl group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group, and when R is an aryloxycarbonyl group or an arylaminocarbonyl group, the aryl moiety thereof may have a substituent. Hereinafter the same shall apply.]
- The respective groups and terms defined in this specification will be shown below.
- The “halogen” refers to fluorine, chlorine, bromine or iodine.
- The “alkyl” refers to straight-chain or branched alkyl having 1 to 6 carbon atoms. Specific examples thereof include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl and the like.
- The “alkoxy” refers to straight-chain or branched alkoxy having 1 to 6 carbon atoms. Specific examples thereof include methoxy, ethoxy, n-propoxy, n-butoxy, n-pentyloxy, n-hexyloxy, isopropoxy, isobutoxy, sec-butoxy, tert-butoxy, isopentyloxy and the like.
- The “aryl” refers to monocyclic aromatic hydrocarbon, or bicyclic or tricyclic condensed polycyclic aromatic hydrocarbon having 6 to 14 carbon atoms. Specific examples thereof include phenyl, naphthyl, anthryl, phenanthryl and the like.
- The “aryloxy” refers to monocyclic aromatic hydrocarbonoxy, or bicyclic or tricyclic condensed polycyclic aromatic hydrocarbonoxy having 6 to 14 carbon atoms. Specific examples thereof include phenoxy, naphthyloxy, anthryloxy, phenanthryloxy and the like.
- The “alkylamino” refers to monoalkylamino or dialkylamino having 1 to 12 carbon atoms. Specific examples thereof include methylamino, ethylamino, dimethylamino, dihexylamino and the like.
- The “arylamino” refers to monoarylamino or diarylamino having 6 to 28 carbon atoms. Specific examples thereof include phenylamino, naphthylamino, methylphenylamino, ethylphenylamino, diphenylamino, dianthrylamino and the like.
- In the case where R is an “aryloxycarbonyl group” or an “arylaminocarbonyl group”, the aryl moiety thereof may have a substituent. As the substituent, an atom or a group selected from a halogen atom, an alkyl group, a halogenated alkyl group and an alkoxy group is preferred, and the number of the substituents is preferably 1 to 3.
- A further more preferred fluorine-containing prostaglandin F2α derivative is, for example, a 15,15-difluoroprostaglandin F2α derivative of the above-mentioned general formula (I) in which R represents a carboxy group or a salt group thereof or an alkoxycarbonyl group.
- A particularly preferred fluorine-containing prostaglandin F2α derivative is, for example, a 15,15-difluoroprostaglandin F2α derivative of the above-mentioned general formula (I) in which R represents a carboxy group or a salt group thereof or an isopropoxycarbonyl group.
- In addition, another preferred compound is, for example, a 15-monofluoroprostaglandin F2α derivative described in the above-mentioned WO 98/12175.
- These prostaglandin F2α derivatives can be in the form of a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid or phosphoric acid, an organic acid such as acetic acid, fumalic acid, maleic acid, succinic acid or citric acid, an alkali metal such as lithium, sodium or potassium, an alkaline earth metal such as calcium or magnesium, ammonia or the like. These salts are also included in the present invention.
- In the present invention, the “retinal neuronal cell” means a neuronal cell involved in the transmission of visual signal to the brain. Specifically, it means a photoreceptor cell, a horizontal cell, a bipolar cell, an optic ganglion cell, an amacrine cell or the like.
- In the present invention, the “eye disease” means an eye disease associated with retinal neuronal cell damage.
- Specifically, it means abnormal visual field, retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, glaucoma, macular degeneration, retinitis pigmentosa, Leber's disease or the like, and preferably it means abnormal visual field, retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa or Leber's disease.
- The protective agent for a retinal neuronal cell of the present invention can be administered orally or parenterally. Examples of the dosage form for administration include an eye drop, an ophthalmic ointment, an injection, a tablet, a capsule, a granule, a powder, and the like, and particularly preferred is an eye drop. Such a preparation can be prepared by any of widely used techniques, for example, a technique disclosed in JP-A-59-1418, JP-T-3-501025, JP-T-8-501310, JP-A-10-182465, WO 98/12175, European Patent Application Publication No. 850926, JP-A-2004-002462, JP-A-10-259179, JP-A-2002-293771, JP-A-2003-321442, WO 2/22131 or the like.
- For example, an eye drop can be prepared using a tonisity agent such as sodium chloride or concentrated glycerin, a buffer such as sodium phosphate or sodium acetate, a surfactant such as polyoxyethylene sorbitan monooleate, polyoxyl 40 stearate or polyoxyethylene hydrogenated castor oil, a stabilizer such as sodium citrate or sodium edetate, a preservative such as benzalkonium chloride or paraben according to need. The pH of the eye drop is permitted as long as it falls within the range that is acceptable as an ophthalmic preparation. Preferred pH is in the range of from 4 to 8.
- An ophthalmic ointment can be prepared using a widely used base such as white soft paraffin or liquid paraffin according to need.
- Further, an oral preparation such as a tablet, a capsule, a granule or a powder can be prepared using an extender such as lactose, crystalline cellulose, starch or a vegetable oil, a lubricant such as magnesium stearate or talc, a binder such as hydroxypropyl cellulose, or polyvinylpyrrolidone, a disintegrant such as carboxymethyl cellulose calcium or low-substituted hydroxypropylmethyl cellulose, a coating agent such as hydroxypropylmethyl cellulose, macrogol or a silicone resin, a film forming agent such as gelatin film, or the like according to need.
- The dose can be appropriately selected depending on the symptoms, age, dosage form and the like. An eye drop may be instilled once to several times a day at a concentration of from 0.00001 to 1% (w/v), preferably from 0.0001 to 1% (w/v). An oral preparation may be administered once or divided into several times at a dose of generally from 0.01 to 5000 mg per day, preferably from 0.1 to 1000 mg per day.
- As will be described in detail in the section of Pharmacological Test below, an effect of a prostaglandin F2α derivative on glutamate-induced retinal neuronal cell death was examined using rat fetal retinal neuronal cells. As a result, the prostaglandin F2α derivative inhibited the glutamate-induced retinal neuronal cell death in a concentration-dependent manner. That is, the prostaglandin F2α derivative has an action of protecting a retinal neuronal cell, and is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage.
- Hereinafter, preparation examples of the present invention and results of a pharmacological test will be described. However, these examples are described for the purpose of understanding the present invention better and are not meant to limit the scope of the present invention.
- Hereinafter, examples of general preparations containing a prostaglandin F2α derivative according to the present invention will be described.
-
1) Eye drop (in 100 mL) Prostaglandin F2α derivative 10 mg Concentrated glycerin 2500 mg Polysorbate 80 2000 mg Sodium phosphate monobasic dihydrate 200 mg Sterile purified water q.s. 1 N hydrochloric acid or 1 N sodium hydroxide q.s. pH 6.0 - A desired eye drop can be obtained by appropriately changing the kinds and the amounts of the prostaglandin F2α derivative and additives.
-
2) Ophthalmic ointment (in 100 g) Prostaglandin F2α derivative 0.1 g Liquid paraffin 20 g White soft paraffin 77.9 g Purified lanolin 2 g - A desired ophthalmic ointment can be obtained by appropriately changing the kinds and the amounts of the prostaglandin F2α derivative and additives.
- In order to find a new pharmaceutical application of a prostaglandin F2α derivative, by using rat fetal retinal neuronal cells, an effect of a prostaglandin F2α derivative on protecting retinal neuronal cells against glutamate-induced retinal neuronal cell death was evaluated and examined.
- Incidentally, as the prostaglandin F2α derivative which is a test compound, 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranor-prostaglandin F2α was used.
- A pregnant SD rat was subjected to laparotomy under systemic anesthesia, and the uterus was transferred to a dish containing Hanks's balanced salt solution (HBSS). A rat fetus was isolated from the uterus, and the eyeballs of the rat fetus were taken out. The retina was isolated from the eyeballs under a stereoscopic microscope and cut into pieces with a surgical knife. Then, the retina was further broken down to the cellular level and passed through a nylon mesh (No. 305, manufactured by NBC Industries Co., Ltd.) to remove cell aggregates, and then, the resulting filtrate was centrifuged at 1000 rpm for 4 minutes. The supernatant was removed, and an appropriate amount of a modified Eagle's medium (MEM) containing 10% fetal bovine serum (FBS) was added to the remaining cells to suspend them. After the cell number was counted with a hemocytometer, an MEM medium containing 10% FBS was added thereto, whereby a cell suspension with a cell density of 0.8×106 cells/mL was obtained. The cell suspension was inoculated in an amount of 80 μL each into polyethylenimine-coated plastic discs, and the discs were allowed to stand in an incubator (37° C., 5% CO2). The day of cell inoculation was designated as day 1 of culture, and medium replacement was carried out on even number days. Incidentally, up to day 4, an MEM medium containing 10% FBS was used, and after day 8, an MEM medium containing 10% horse serum (HS) was used. Incidentally, on day 6, 6 mL of a medium containing cytarabine (Ara-C) (1.5×10−5 M in an MEM medium containing 10% FBS) was used for removing proliferative cells.
- 2 mg of the test compound was dissolved in 100% ethanol, and the resulting solution was sequentially diluted with an HS-containing MEM medium, whereby an HS-containing MEM medium containing the test compound at 0.1 nM, 1 nM, 10 nM or 100 nM was prepared.
- 2 mg of the test compound was dissolved in 100% ethanol, and the resulting solution was sequentially diluted with a serum-free MEM medium, whereby a serum-free MEM medium containing the test compound at 0.1 nM, 1 nM, 10 nM or 100 nM was prepared.
- At day 10 of culture, the plastic discs in which cells were inoculated and cultured were transferred to the HS-containing MEM medium containing the test compound and incubated for 24 hours (37° C., 5% CO2). The plastic discs were transferred to a serum-free MEM medium containing 1 mM glutamate and incubated for 10 minutes, and then transferred to the serum-free MEM medium containing the test compound and incubated for 1 hour (37° C., 5% CO2). Then, the cells were stained with a 1.5% trypan blue solution for 10 minutes and fixed by adding a 10% formalin fixative solution thereto. After the cells were washed with a physiological saline solution, stained cells and unstained cells were counted under an inverted microscope.
- Incidentally, a vehicle administration group was prepared by carrying out the same test as described above except that an HS-containing MEM medium was used instead of the above-mentioned HS-containing MEM medium containing the test compound and a serum-free MEM medium was used instead of the above-mentioned serum-free MEM medium containing the test compound.
- Further, an untreated group was prepared by carrying out the same test as described above except that an HS-containing MEM medium was used instead of the above-mentioned HS-containing MEM medium containing the test compound and a serum-free MEM medium was used instead of the above-mentioned serum-free MEM medium containing the test compound, and further a treatment with a serum-free MEM medium containing glutamate was not carried out.
- The survival rate was calculated based on the following calculation equation.
-
Survival rate (%)={(unstained cell number)/(unstained cell number+stained cell number)}×100 - As shown in
FIG. 1 , about 40% cell death of the retinal neuronal cells due to the treatment with glutamate was observed in the vehicle addition group. However, when the HS-containing MEM medium containing the test compound (0.1 nM to 100 mM) was used as a medium, the glutamate-induced retinal neuronal cell death was inhibited in a concentration-dependent manner, and it was confirmed that the test compound has an action of protecting a retinal neuronal cell. -
FIG. 1 is a graph showing the survival rate for each concentration in the case of using the test compound by the addition of glutamate.
Claims (23)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-100348 | 2005-03-31 | ||
JP2005100348 | 2005-03-31 | ||
PCT/JP2006/306826 WO2006106915A1 (en) | 2005-03-31 | 2006-03-31 | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL CONTAINING PROSTAGLANDIN F2α DERIVATIVE AS ACTIVE INGREDIENT |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/306826 A-371-Of-International WO2006106915A1 (en) | 2005-03-31 | 2006-03-31 | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL CONTAINING PROSTAGLANDIN F2α DERIVATIVE AS ACTIVE INGREDIENT |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/199,598 Division US9138438B2 (en) | 2005-03-31 | 2011-09-02 | Method for protecting a retinal neuronal cell |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090234005A1 true US20090234005A1 (en) | 2009-09-17 |
Family
ID=37073466
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/887,037 Abandoned US20090234005A1 (en) | 2005-03-31 | 2006-03-31 | Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient |
US13/199,598 Active US9138438B2 (en) | 2005-03-31 | 2011-09-02 | Method for protecting a retinal neuronal cell |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/199,598 Active US9138438B2 (en) | 2005-03-31 | 2011-09-02 | Method for protecting a retinal neuronal cell |
Country Status (14)
Country | Link |
---|---|
US (2) | US20090234005A1 (en) |
EP (1) | EP1864666B1 (en) |
KR (1) | KR101396731B1 (en) |
CN (2) | CN102293774A (en) |
CA (1) | CA2602573C (en) |
CY (1) | CY1113473T1 (en) |
DK (1) | DK1864666T3 (en) |
ES (1) | ES2389500T3 (en) |
NO (1) | NO339794B1 (en) |
PL (1) | PL1864666T3 (en) |
PT (1) | PT1864666E (en) |
RU (1) | RU2414904C2 (en) |
SI (1) | SI1864666T1 (en) |
WO (1) | WO2006106915A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080033036A1 (en) * | 2003-08-12 | 2008-02-07 | Ryuji Ueno | Composition and Method for Promoting Hair Growth |
US20100203103A1 (en) * | 2007-08-16 | 2010-08-12 | Schepens Eye Research Institute | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
US20120014970A1 (en) * | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
US8715712B2 (en) | 2011-09-14 | 2014-05-06 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US9421126B2 (en) | 2009-06-03 | 2016-08-23 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US9750636B2 (en) | 2012-10-26 | 2017-09-05 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
US10117906B2 (en) | 2009-01-09 | 2018-11-06 | The Schepens Eye Research Institute, Inc. | Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra |
US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
US11224602B2 (en) | 2015-04-13 | 2022-01-18 | Forsight Vision5, Inc. | Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
WO2008133021A1 (en) * | 2007-04-12 | 2008-11-06 | R-Tech Ueno, Ltd. | COMPOSITION FOR AMELIORATING OPTIC NERVE DISORDER COMPRISING PROSTAGLANDIN F2α COMPOUND AS ACTIVE INGREDIENT |
BRPI0918244A2 (en) * | 2008-09-04 | 2015-12-15 | Santen Pharmaceutical Co Ltd E Asahi Glass Company Ltd | hair growth promoting agent; and method for preventing or treating a disease associated with hair. |
US9089579B2 (en) | 2011-01-19 | 2015-07-28 | Topokine Therapeutics, Inc. | Methods and compositions for treating metabolic syndrome |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
NO2753788T3 (en) | 2013-05-10 | 2018-06-16 | ||
WO2014186504A1 (en) | 2013-05-15 | 2014-11-20 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
US4822820A (en) * | 1986-11-24 | 1989-04-18 | Alcon Laboratories, Inc. | Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy |
US5773471A (en) * | 1995-03-10 | 1998-06-30 | R-Tech Ueno, Ltd. | Treatment of optic nerve disorder with prostanoic acid compounds |
US5877211A (en) * | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
US5886035A (en) * | 1996-12-26 | 1999-03-23 | Asahi Glass Company Ltd. | Difluoroprostaglandin derivatives and their use |
US20020025985A1 (en) * | 2000-03-24 | 2002-02-28 | Ryuji Ueno | Apoptosis inhibitor |
US20030105133A1 (en) * | 1995-12-22 | 2003-06-05 | Bigge Christopher F. | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists |
US20040102437A1 (en) * | 2000-02-01 | 2004-05-27 | Atsuya Takami | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
US20040106646A1 (en) * | 2001-04-11 | 2004-06-03 | Yoshiko Takayama | Visual function disorder improving agents |
US20040138286A1 (en) * | 2001-06-12 | 2004-07-15 | Naonori Imazaki | Rho kinase inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0251225A (en) | 1988-08-15 | 1990-02-21 | Shin Etsu Chem Co Ltd | Core tube for semiconductor diffusing furnace |
ES2186670T3 (en) | 1988-09-06 | 2003-05-16 | Pharmacia Ab | PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION. |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
JP3625946B2 (en) * | 1995-03-10 | 2005-03-02 | 株式会社アールテック・ウエノ | Optic neuropathy improving agent |
JP3501310B2 (en) | 1995-03-10 | 2004-03-02 | 日産ディーゼル工業株式会社 | Diesel engine fuel injection tube holding device |
PT857718E (en) * | 1996-06-10 | 2002-11-29 | Sucampo Ag | ENDOTHELINE ANTAGONIST |
JPH1087607A (en) | 1996-09-17 | 1998-04-07 | Asahi Glass Co Ltd | Production fluorine-containing prostaglandin derivative |
JP4004109B2 (en) * | 1996-09-17 | 2007-11-07 | 参天製薬株式会社 | Fluorine-containing prostaglandin derivatives and pharmaceuticals |
ATE221048T1 (en) | 1996-09-17 | 2002-08-15 | Asahi Glass Co Ltd | FLUORINATED PROSTAGLAND DERIVATIVES AND MEDICATIONS |
JPH10259179A (en) | 1996-09-19 | 1998-09-29 | Santen Pharmaceut Co Ltd | Prostaglandins having multi-substituted aryloxy groups and their use |
US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
EP1121932A4 (en) * | 1998-10-13 | 2001-12-19 | Kyowa Hakko Kogyo Kk | Remedies for ocular diseases |
JP4372905B2 (en) | 1999-09-02 | 2009-11-25 | 興和株式会社 | Retinal nerve cell protective agent |
AU2001228863A1 (en) | 2000-01-31 | 2001-08-14 | Santen Pharmaceutical Co. Ltd. | Remedies for ophthalmic diseases |
KR100854056B1 (en) | 2000-09-13 | 2008-08-26 | 산텐 세이야꾸 가부시키가이샤 | Eye drops |
JP2002293771A (en) | 2001-03-30 | 2002-10-09 | Asahi Glass Co Ltd | New ether-type difluoroprostaglandin derivative or its salt |
WO2003004058A1 (en) | 2001-07-02 | 2003-01-16 | Santen Pharmaceutical Co., Ltd. | OPTIC NERVE PROTECTING AGENTS CONTAINING α1 RECEPTOR BLOCKER AS THE ACTIVE INGREDIENT |
JP2003146904A (en) | 2001-11-08 | 2003-05-21 | Nippon Shinyaku Co Ltd | Therapeutic agent for glaucoma |
JP2003321442A (en) | 2002-04-24 | 2003-11-11 | Santen Pharmaceut Co Ltd | New difluoroprostaglandin amide derivative |
JP4110324B2 (en) | 2003-10-15 | 2008-07-02 | 宇部興産株式会社 | New indazole derivatives |
-
2006
- 2006-03-31 CN CN201110176745A patent/CN102293774A/en active Pending
- 2006-03-31 EP EP06730774A patent/EP1864666B1/en active Active
- 2006-03-31 CA CA2602573A patent/CA2602573C/en active Active
- 2006-03-31 ES ES06730774T patent/ES2389500T3/en active Active
- 2006-03-31 PT PT06730774T patent/PT1864666E/en unknown
- 2006-03-31 KR KR1020077023372A patent/KR101396731B1/en active IP Right Grant
- 2006-03-31 DK DK06730774.4T patent/DK1864666T3/en active
- 2006-03-31 SI SI200631410T patent/SI1864666T1/en unknown
- 2006-03-31 CN CN2006800107892A patent/CN101151034B/en active Active
- 2006-03-31 WO PCT/JP2006/306826 patent/WO2006106915A1/en active Application Filing
- 2006-03-31 PL PL06730774T patent/PL1864666T3/en unknown
- 2006-03-31 US US11/887,037 patent/US20090234005A1/en not_active Abandoned
- 2006-03-31 RU RU2007140309/15A patent/RU2414904C2/en active
-
2007
- 2007-10-29 NO NO20075464A patent/NO339794B1/en not_active IP Right Cessation
-
2011
- 2011-09-02 US US13/199,598 patent/US9138438B2/en active Active
-
2012
- 2012-10-16 CY CY20121100958T patent/CY1113473T1/en unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
US4822820A (en) * | 1986-11-24 | 1989-04-18 | Alcon Laboratories, Inc. | Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy |
US5773471A (en) * | 1995-03-10 | 1998-06-30 | R-Tech Ueno, Ltd. | Treatment of optic nerve disorder with prostanoic acid compounds |
US20030105133A1 (en) * | 1995-12-22 | 2003-06-05 | Bigge Christopher F. | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists |
US5886035A (en) * | 1996-12-26 | 1999-03-23 | Asahi Glass Company Ltd. | Difluoroprostaglandin derivatives and their use |
US5985920A (en) * | 1996-12-26 | 1999-11-16 | Asahi Glass Company Ltd. | Difluoroprostaglandin derivatives and their use |
US5877211A (en) * | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
US20040102437A1 (en) * | 2000-02-01 | 2004-05-27 | Atsuya Takami | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
US20020025985A1 (en) * | 2000-03-24 | 2002-02-28 | Ryuji Ueno | Apoptosis inhibitor |
US20040106646A1 (en) * | 2001-04-11 | 2004-06-03 | Yoshiko Takayama | Visual function disorder improving agents |
US20040138286A1 (en) * | 2001-06-12 | 2004-07-15 | Naonori Imazaki | Rho kinase inhibitors |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8686035B2 (en) | 2003-08-12 | 2014-04-01 | R-Tech Ueno, Ltd. | Composition and method for promoting hair growth |
US20080033036A1 (en) * | 2003-08-12 | 2008-02-07 | Ryuji Ueno | Composition and Method for Promoting Hair Growth |
US20100203103A1 (en) * | 2007-08-16 | 2010-08-12 | Schepens Eye Research Institute | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
US10105441B2 (en) * | 2007-08-16 | 2018-10-23 | The Schepens Eye Research Institute, Inc. | Method for inhibiting or reducing dry eye disease by IL-1Ra |
US20120014970A1 (en) * | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
US10117906B2 (en) | 2009-01-09 | 2018-11-06 | The Schepens Eye Research Institute, Inc. | Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra |
US10004636B2 (en) | 2009-06-03 | 2018-06-26 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US10736774B2 (en) | 2009-06-03 | 2020-08-11 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US9421126B2 (en) | 2009-06-03 | 2016-08-23 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US9937073B2 (en) | 2010-06-01 | 2018-04-10 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US8939948B2 (en) | 2010-06-01 | 2015-01-27 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
US8715712B2 (en) | 2011-09-14 | 2014-05-06 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US10835416B2 (en) | 2011-09-14 | 2020-11-17 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US9750636B2 (en) | 2012-10-26 | 2017-09-05 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
US10456293B2 (en) | 2012-10-26 | 2019-10-29 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
US11224602B2 (en) | 2015-04-13 | 2022-01-18 | Forsight Vision5, Inc. | Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent |
Also Published As
Publication number | Publication date |
---|---|
NO20075464L (en) | 2007-12-18 |
PT1864666E (en) | 2012-09-06 |
US20120010288A1 (en) | 2012-01-12 |
US9138438B2 (en) | 2015-09-22 |
WO2006106915A1 (en) | 2006-10-12 |
ES2389500T3 (en) | 2012-10-26 |
DK1864666T3 (en) | 2012-10-29 |
PL1864666T3 (en) | 2013-02-28 |
KR20070116632A (en) | 2007-12-10 |
CA2602573C (en) | 2013-10-08 |
RU2007140309A (en) | 2009-05-10 |
EP1864666B1 (en) | 2012-08-15 |
CA2602573A1 (en) | 2006-10-12 |
KR101396731B1 (en) | 2014-05-19 |
RU2414904C2 (en) | 2011-03-27 |
CN102293774A (en) | 2011-12-28 |
EP1864666A1 (en) | 2007-12-12 |
CN101151034A (en) | 2008-03-26 |
EP1864666A4 (en) | 2008-04-02 |
NO339794B1 (en) | 2017-01-30 |
CN101151034B (en) | 2012-06-06 |
CY1113473T1 (en) | 2016-06-22 |
SI1864666T1 (en) | 2012-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9138438B2 (en) | Method for protecting a retinal neuronal cell | |
ES2370751T3 (en) | PROFILACTIC OR THERAPEUTIC AGENT FOR MACULAR DEGENERATION ASSOCIATED WITH AGE. | |
KR20100016270A (en) | Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient | |
EP3318280A1 (en) | Depot preparation containing citric acid ester | |
US20110130388A1 (en) | Prophylactic or therapeutic agent for axial myopia | |
US20240091249A1 (en) | Methods for the use of 5'-adenosine diphosphate ribose (adpr) | |
JP5100025B2 (en) | Retinal nerve cell protective agent containing prostaglandin F2α derivative as an active ingredient | |
JP7250685B2 (en) | Medicine containing pyridylaminoacetic acid compound | |
US20040192699A1 (en) | Optic nerve protecting agents containing alpha1 receptor blocker as active ingredient | |
JP2011144111A (en) | Axial myopia-preventing or treating agent | |
AU2002309280B2 (en) | Agent for protection of retinal neurons | |
AU2002309280A1 (en) | Agent for protection of retinal neurons | |
WO2009110526A1 (en) | Prophylactic or therapeutic agent for optic nerve disorders comprising 3',5-di-2-propenyl-(1,1'-biphenyl)-2,4'-diol as active ingredient | |
JP4393863B2 (en) | Optic nerve cell protective agent | |
KR20030063387A (en) | Therapeutic and/or preventive agents for diseases due to retinal ischemia | |
JP2001240543A (en) | Medicine for treatment and/or prevention of ischemic retinopathy and disease of retina or optic nerve | |
JP2017218384A (en) | Pharmaceutical composition for prevention or treatment of retinal disease | |
JPH10120569A (en) | Preventive and therapeutic agent for eye disease | |
US20130267488A1 (en) | Pharmaceutical formulation having neuroprotective activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANTEN PHARMACEUTICAL CO., LTD, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ISHIDA, MARUHIRO;SHIMAZAKI, ATSUSHI;REEL/FRAME:019944/0049 Effective date: 20070718 Owner name: ASAHI GLASS COMPANY LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ISHIDA, MARUHIRO;SHIMAZAKI, ATSUSHI;REEL/FRAME:019944/0049 Effective date: 20070718 |
|
AS | Assignment |
Owner name: ASAHI GLASS COMPANY, LIMITED, JAPAN Free format text: CORPORATE ADDRESS CHANGE;ASSIGNOR:ASAHI GLASS COMPANY, LIMITED;REEL/FRAME:027197/0541 Effective date: 20110816 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |